Nintedanib Teva (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, PDGFR and FGFR—thereby inhibiting signaling that promotes fibroblast growth, migration, and transformation. This dual antifibrotic and anti‑angiogenic action reduces scar tissue formation in the lungs and limits blood‑vessel support for tumor cells, contributing to its therapeutic effects.

The specific dose and dosing schedule for Nintedanib Teva are determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and other individual factors. Healthcare professionals follow the approved labeling and adjust the regimen as needed; patients should not alter the dose without medical advice.

Safety data for Nintedanib Teva in pregnancy and lactation are limited, and the product is generally not recommended for use in these situations. The drug should only be prescribed to pregnant or nursing women if the potential benefits justify the possible risks, and a healthcare provider should discuss alternatives and monitoring strategies.

To request Nintedanib Teva, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nintedanib differs from other antifibrotic drugs such as pirfenidone by targeting a broader range of tyrosine‑kinase receptors, offering both antifibrotic and anti‑angiogenic effects. Clinical trials have shown comparable efficacy in slowing lung‑function decline, but the side‑effect profile varies; for example, gastrointestinal events are more common with nintedanib, while photosensitivity is more typical of pirfenidone.

Nintedanib Teva should be stored at ambient temperature below 25 °C (77 °F). Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed when not in use. Do not refrigerate or freeze the tablets, as temperature extremes can affect stability.

Nintedanib Teva is taken orally, usually as whole tablets swallowed with water. The medication is typically taken with food to reduce gastrointestinal discomfort, but patients should follow the specific instructions provided by their prescriber. Consistent daily dosing at the same time each day helps maintain stable drug levels.

Serious risks include hepatic failure, severe bleeding, gastrointestinal perforation, arterial thromboembolism, and worsening of interstitial lung disease. Patients should be monitored regularly for signs of liver injury, bleeding events, abdominal pain, and any unexpected respiratory decline. Prompt medical attention is essential if any of these serious adverse events occur.

Nintedanib Teva is contraindicated in patients with severe hepatic impairment, active bleeding disorders, or known hypersensitivity to the drug or its excipients. It should also be used with caution in individuals with moderate liver disease, uncontrolled cardiovascular conditions, or those taking strong CYP3A4 or P‑gp inhibitors. A qualified healthcare professional must assess suitability before initiating therapy.